| Name | Title | Contact Details |
|---|
Foundations Associates is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Brentwood, TN. To find more information about Foundations Associates, please visit www.dualdiagnosis.org
Oxylent has taken the multivitamin category by storm with its award-winning 5-in-1 formula that delivers vitamins, minerals, antioxidants, amino acids and electrolytes in one refreshing drink. Without the use of sugar, gluten, artificial additives, preservatives, dairy, caffeine, binders, or anti-caking agents, Oxylent is known in the market for using only the highest quality ingredients. Oxylent is the only effervescent multivitamin to be awarded Albion’s Gold Medallion, recognizing excellence in mineral formulation. The product contains no sugar and is sweetened with all-natural stevia, a plant-based sweetener that provides the sweetness of sugar without the calories or increase in blood sugar levels. Plus, Oxylent is 100 percent free of gluten, dairy, soy, GMOs and caffeine.
Interstate Imaging is a Evansville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BARRX, Inc is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. BARRX, Inc is based in Sunnyvale, CA. You can find more information on BARRX, Inc at www.barrx.com
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.